COGENT BIOSCIENCES, INC


Associated tags: Division, HER2/neu, Webcast, KIT, APEX, Dana–Farber Cancer Institute, Society, Social media, Pharmaceutical industry, ASH, B cell, Leukemia, FGFR2, Cogent, Mutation, Patient, GIST, PEAK, PR, CI

Locations: WALTHAM, MA, US, NEW ORLEANS, LA, WASHINGTON

Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

Retrieved on: 
Sunday, December 11, 2022
Division, PPR, Patient, Mast cell leukemia, Clinical trial, FGFR2, TKI, BID, B cell, CRH, HER2/neu, Edema, Intracranial hemorrhage, Dana–Farber Cancer Institute, APEX, Safety, Webcast, Part Two, CoGeNT, ASH, GIST, CR, ORR, Neutropenia, Thrombocytopenia, Risk, ASM, Government budget balance, Society, MCL, Mutation, PEAK, Social media, CI, Anemia, KIT, PR, Medical imaging, Pharmaceutical industry, Health insurance, Leukemia, Cogent

WALTHAM, Mass. and BOULDER, Colo., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated clinical data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). The data are being presented in an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, LA. 

Key Points: 
  • and BOULDER, Colo., Dec. 11, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced positive updated clinical data from its ongoing Phase 2 APEX clinical trial evaluating the selective KIT D816V inhibitor bezuclastinib in patients with advanced systemic mastocytosis (AdvSM).
  • Patients were enrolled with the following sub-types: three patients with aggressive systemic mastocytosis (ASM), 12 patients with systemic mastocytosis with associated hematologic neo-plasm (SM-AHN), and one patient with mast cell leukemia (MCL).
  • In addition, Cogent continues to actively enroll patients in SUMMIT, a Phase 2 clinical trial with bezuclastinib for patients with non-advanced systemic mastocytosis (NonAdvSM), and PEAK, a registrational randomized, open-label, global, Phase 3 clinical trial in patients with imatinib-resistant Gastrointestinal Stromal Tumors (GIST).
  • ET (7:00 a.m. CT) to discuss today’s updated clinical data from the ongoing APEX trial.

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis

Retrieved on: 
Monday, December 5, 2022
Question answering, B cell, HER2/neu, APEX, Dana–Farber Cancer Institute, Webcast, ASH, GIST, Question, Society, Mutation, Social media, Division, Patient, KIT, FGFR2, Pharmaceutical industry, Leukemia, Cogent

ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 64th American Society of Hematology (ASH) Annual Meeting.

Key Points: 
  • ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 64th American Society of Hematology (ASH) Annual Meeting.
  • The live webcast of the event can be accessed on the Investors and Media page of Cogent’s website at investors.cogentbio.com .
  • KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells.
  • Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com.